Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Neuro- and immunomodulatory steroids and other biochemical markers in drug-naive schizophrenia patients and the effect of treatment with atypical antipsychotics

Marie Bičíková, Richard Hampl, Martin Hill, Daniela Řípova, Pavel Mohr, Zdeněk Putz, Peter Vanuga

. 2011 ; 32 (2) : 141-147.

Jazyk angličtina Země Švédsko

Typ dokumentu klinické zkoušky, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12027556

Grantová podpora
NS9835 MZ0 CEP - Centrální evidence projektů

OBJECTIVE: Serum levels of neuro- and immunomodulatory adrenal steroids together with selected hormonal, lipid and other relevant biochemical parameters were investigated to examine the differences between first-episode schizophrenia patients and age-matched healthy subjects, and the effect of treatment with atypical antipsychotics. METHODS: The patient´s group consisted of 22 drug-naive patients (13 men and 9 women), diagnosed with schizophrenia according to ICD-10 criteria, before and after six-months treatment with atypical antipsychotics of olanzapine or non-olanzapine type. Biochemical markers included steroids cortisol, dehydroepiandrosterone, its sulfate, 7-hydroxylated metabolites of dehydroepiandrosterone, prolactin, thyrotropin, free thyroxine, autoantibodies against thyroid peroxidase and thyroglobulin, glucose levels, four major lipid parameters, homocysteine and three other aminothiols. Steroids, prolactin and thyroid parameters were determined by radioimmunoassays, the other markers by standard biochemical methods. RESULTS: Significantly lower dehydroepiandrosterone sulfate and of 7α-hydroxy- dehydroepiandrosterone levels than in controls were found in male patients. In the female group, the only difference in steroid spectra was significantly higher cortisolemia in the patients. The patients had also higher titres of autoantibodies against thyroid peroxidase. Compared to controls, the patients displayed worse lipid spectra, and higher homocysteinemia. Medication did not lead to significant changes in the parameters, with the exception of expected increase in prolactin levels in non-olanzapine treated subgroups. CONCLUSION: Lower levels of 7α-hydroxydehydroepiandrosterone, abundant especially in brain, determined for the first time in schizophrenia patients, are in agreement with recent opinion of their neuroprotective and immunoprotective role. High levels of autoantibodies against thyroid peroxidase in the patients support the autoimmunity hypothesis of schizophrenia.

000      
00000naa a2200000 a 4500
001      
bmc12027556
003      
CZ-PrNML
005      
20170411101824.0
007      
ta
008      
120817s2011 sw f 000 0#eng||
009      
AR
035    __
$a (PubMed)21552193
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sw
100    1_
$a Bičíková, Marie $u Institute of Endocrinology, 1st Medical Faculty, Charles University, Prague, Czech Republic. rhampl@endo.cz
245    10
$a Neuro- and immunomodulatory steroids and other biochemical markers in drug-naive schizophrenia patients and the effect of treatment with atypical antipsychotics / $c Marie Bičíková, Richard Hampl, Martin Hill, Daniela Řípova, Pavel Mohr, Zdeněk Putz, Peter Vanuga
520    9_
$a OBJECTIVE: Serum levels of neuro- and immunomodulatory adrenal steroids together with selected hormonal, lipid and other relevant biochemical parameters were investigated to examine the differences between first-episode schizophrenia patients and age-matched healthy subjects, and the effect of treatment with atypical antipsychotics. METHODS: The patient´s group consisted of 22 drug-naive patients (13 men and 9 women), diagnosed with schizophrenia according to ICD-10 criteria, before and after six-months treatment with atypical antipsychotics of olanzapine or non-olanzapine type. Biochemical markers included steroids cortisol, dehydroepiandrosterone, its sulfate, 7-hydroxylated metabolites of dehydroepiandrosterone, prolactin, thyrotropin, free thyroxine, autoantibodies against thyroid peroxidase and thyroglobulin, glucose levels, four major lipid parameters, homocysteine and three other aminothiols. Steroids, prolactin and thyroid parameters were determined by radioimmunoassays, the other markers by standard biochemical methods. RESULTS: Significantly lower dehydroepiandrosterone sulfate and of 7α-hydroxy- dehydroepiandrosterone levels than in controls were found in male patients. In the female group, the only difference in steroid spectra was significantly higher cortisolemia in the patients. The patients had also higher titres of autoantibodies against thyroid peroxidase. Compared to controls, the patients displayed worse lipid spectra, and higher homocysteinemia. Medication did not lead to significant changes in the parameters, with the exception of expected increase in prolactin levels in non-olanzapine treated subgroups. CONCLUSION: Lower levels of 7α-hydroxydehydroepiandrosterone, abundant especially in brain, determined for the first time in schizophrenia patients, are in agreement with recent opinion of their neuroprotective and immunoprotective role. High levels of autoantibodies against thyroid peroxidase in the patients support the autoimmunity hypothesis of schizophrenia.
650    _2
$a dospělí $7 D000328
650    _2
$a protilátky $x krev $x imunologie $7 D000906
650    _2
$a antipsychotika $x terapeutické užití $7 D014150
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a dehydroepiandrosteron $x analogy a deriváty $x krev $7 D003687
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a homocystein $x krev $7 D006710
650    _2
$a lidé $7 D006801
650    _2
$a hydrokortison $x krev $7 D006854
650    _2
$a imunologické faktory $x krev $7 D007155
650    _2
$a jodidperoxidasa $x imunologie $7 D007453
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a neurotransmiterové látky $x krev $7 D018377
650    _2
$a prolaktin $x krev $7 D011388
650    _2
$a schizofrenie $x krev $x farmakoterapie $7 D012559
650    _2
$a pohlavní dimorfismus $7 D012727
650    _2
$a steroidy $x krev $7 D013256
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hampl, Richard $u Institute of Endocrinology, 1st Medical Faculty, Charles University, Prague, Czech Republic
700    1_
$a Hill, Martin $u Institute of Endocrinology, 1st Medical Faculty, Charles University, Prague, Czech Republic
700    1_
$a Řípová, Daniela $u Prague Psychiatric Centre, Prague, Czech Republic
700    1_
$a Mohr, Pavel $u Prague Psychiatric Centre, Prague, Czech Republic
700    1_
$a Putz, Zdeněk $u National Institute of Endocrinology and Diabetology, Lubochňa, Slovak Republic
700    1_
$u Vanuga, Peter $a National Institute of Endocrinology and Diabetology, Lubochňa, Slovak Republic
773    0_
$w MED00168352 $t Neuro endocrinology letters $x 0172-780X $g Roč. 32, č. 2 (2011), s. 141-147
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21552193 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120817 $b ABA008
991    __
$a 20170411102123 $b ABA008
999    __
$a ok $b bmc $g 949598 $s 784902
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 32 $c 2 $d 141-147 $i 0172-780X $m Neuro-endocrinology letters $n Neuro-endocrinol. lett. $x MED00168352
GRA    __
$a NS9835 $p MZ0
LZP    __
$a Pubmed-20120817/11/03

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...